Lyme Disease (Borrelia burgdorferi)
Screening and Confirmation

fda_cleared

GSD offers both a superior Enzyme Immunoassay (EIA) screen (first tier) test and highly specific immunoblot confirmation (second tier) tests to fulfill the CDC’s recommended Lyme disease diagnostic process. The EIA screen test is simple and easy-to-use, with a fast protocol, and the IgG and IgM  immunoblot confirmation tests offer numerous improvements compared to traditional Western blot technology.

Both the Lyme screen and confirmation tests are FDA cleared and can be easily automated.

 

NEW Borrelia burgdorferi IgG/IgM
EIA SCREEN TEST (FDA Cleared)

GSD EIA ADVANTAGES

Superior Sensitivity – Includes antigens from B. burgdorferi strains B31 and 2591

Optimal Specificity – Contains VIsE immunogenic lipoprotein

Polyvalent Screen  – Both IgG and IgM antibodies are included

Automation – Simple procedure is easy to automate

Fast Protocol  – 15min/15min/15min

Convenient  – Kit includes ready-to-use controls for ease of use

LYME IgG and IgM IMMUNOBLOT
CONFIRMATION TESTS (FDA Cleared)

Immunoblot Advantages

  • Discrete Antigen Application – Antigen applied in tightly defined, discrete positions on each strip.
  • Native Antigen Structure – The 3D (tertiary) structure is maintained for Immunoblots. Western blot proteins are denatured, and only their primary structure remains intact. Antibodies bond with proteins in their native structure.
  • Intuitive Results – Easy-to-read, precisely defined results. No special Band Locater or subjective judgment required.
  • Easy Handling – Strips fixed in a numbered booklet (50 strips per booklet).
  • Durable Strips – Strip booklet stabilized with plastic backing.
  • Automation – Standardized strips are suitable for automation.

Immunoblots vs. Western Blots

Immunoblot strips offer easy handling, simple procedures and intuitive interpretation. Results are clear and easy to interpret.

immunoblot

Traditional “Western Blots” are not intuitive to read and require a Band Locator to interpret results.

Borrelia burgdorferi B31 Added to CAP Survey

GSD’s Borrelia burgdorferi B31 Immunoblots for the confirmation of Lyme disease have been added to the CAP Proficiency Testing Program as part of the Tick-Transmitted Disease (TTD) panel.

+ OVERVIEW

GSD offers both a superior Enzyme Immunoassay (EIA) screen (first tier) test and highly specific immunoblot confirmation (second tier) tests to fulfill the CDC’s recommended Lyme disease diagnostic process. The EIA screen test is simple and easy-to-use, with a fast protocol, and the IgG and IgM  immunoblot confirmation tests offer numerous improvements compared to traditional Western blot technology.

Both the Lyme screen and confirmation tests are FDA cleared and can be easily automated.

 

+ SCREEN

NEW Borrelia burgdorferi IgG/IgM
EIA SCREEN TEST (FDA Cleared)

GSD EIA ADVANTAGES

Superior Sensitivity – Includes antigens from B. burgdorferi strains B31 and 2591

Optimal Specificity – Contains VIsE immunogenic lipoprotein

Polyvalent Screen  – Both IgG and IgM antibodies are included

Automation – Simple procedure is easy to automate

Fast Protocol  – 15min/15min/15min

Convenient  – Kit includes ready-to-use controls for ease of use

+ CONFIRMATION

LYME IgG and IgM IMMUNOBLOT
CONFIRMATION TESTS (FDA Cleared)

Immunoblot Advantages

  • Discrete Antigen Application – Antigen applied in tightly defined, discrete positions on each strip.
  • Native Antigen Structure – The 3D (tertiary) structure is maintained for Immunoblots. Western blot proteins are denatured, and only their primary structure remains intact. Antibodies bond with proteins in their native structure.
  • Intuitive Results – Easy-to-read, precisely defined results. No special Band Locater or subjective judgment required.
  • Easy Handling – Strips fixed in a numbered booklet (50 strips per booklet).
  • Durable Strips – Strip booklet stabilized with plastic backing.
  • Automation – Standardized strips are suitable for automation.

Immunoblots vs. Western Blots

Immunoblot strips offer easy handling, simple procedures and intuitive interpretation. Results are clear and easy to interpret.

immunoblot

Traditional “Western Blots” are not intuitive to read and require a Band Locator to interpret results.

Borrelia burgdorferi B31 Added to CAP Survey

GSD’s Borrelia burgdorferi B31 Immunoblots for the confirmation of Lyme disease have been added to the CAP Proficiency Testing Program as part of the Tick-Transmitted Disease (TTD) panel.